CN116056710A - 用tlr激动剂治疗癌症 - Google Patents

用tlr激动剂治疗癌症 Download PDF

Info

Publication number
CN116056710A
CN116056710A CN202180053175.7A CN202180053175A CN116056710A CN 116056710 A CN116056710 A CN 116056710A CN 202180053175 A CN202180053175 A CN 202180053175A CN 116056710 A CN116056710 A CN 116056710A
Authority
CN
China
Prior art keywords
compound
patient
treatment
dose
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180053175.7A
Other languages
English (en)
Chinese (zh)
Inventor
李立新
R·安德特巴克卡
黄涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Birdie Biopharmaceuticals Inc Cayman Islands
Original Assignee
Birdie Biopharmaceuticals Inc Cayman Islands
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Birdie Biopharmaceuticals Inc Cayman Islands filed Critical Birdie Biopharmaceuticals Inc Cayman Islands
Publication of CN116056710A publication Critical patent/CN116056710A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180053175.7A 2020-08-26 2021-08-26 用tlr激动剂治疗癌症 Pending CN116056710A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063070376P 2020-08-26 2020-08-26
US63/070,376 2020-08-26
PCT/US2021/047826 WO2022047083A1 (en) 2020-08-26 2021-08-26 Cancer treatment with tlr agonist

Publications (1)

Publication Number Publication Date
CN116056710A true CN116056710A (zh) 2023-05-02

Family

ID=80355767

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180053175.7A Pending CN116056710A (zh) 2020-08-26 2021-08-26 用tlr激动剂治疗癌症

Country Status (8)

Country Link
US (1) US20230346775A1 (https=)
EP (1) EP4203962A4 (https=)
JP (1) JP2023539625A (https=)
KR (1) KR20230057409A (https=)
CN (1) CN116056710A (https=)
AU (1) AU2021332350A1 (https=)
CA (1) CA3192776A1 (https=)
WO (1) WO2022047083A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899539B (zh) 2014-01-10 2021-11-09 博笛生物科技有限公司 用于免疫疗法的化合物和组合物
CN115252792A (zh) 2016-01-07 2022-11-01 博笛生物科技有限公司 用于治疗肿瘤的抗-egfr组合
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
IL312120B2 (en) 2017-06-23 2025-06-01 Birdie Biopharmaceuticals Inc Pharmaceutical compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899537A (zh) * 2014-01-10 2016-08-24 博笛生物科技（北京）有限公司 靶向表达egfr的肿瘤的化合物和组合物
CN110769827A (zh) * 2017-06-23 2020-02-07 博笛生物科技有限公司 药物组合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3166976B2 (en) * 2014-07-09 2026-04-08 Birdie Biopharmaceuticals Inc. Anti-pd-l1 combinations for treating tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899537A (zh) * 2014-01-10 2016-08-24 博笛生物科技（北京）有限公司 靶向表达egfr的肿瘤的化合物和组合物
CN110769827A (zh) * 2017-06-23 2020-02-07 博笛生物科技有限公司 药物组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAISOVÁ V, ET AL.: ""Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis"", 《INTERNATIONAL IMMUNOPHARMACOLOGY》, vol. 59, 30 May 2018 (2018-05-30), pages 86 - 96, XP055912927, DOI: 10.1016/j.intimp.2018.03.038 *
MEYER T, SURBER C, FRENCH L E, ET AL.: ""Resiquimod, a topical drug for viral skin lesions and skin cancer"", 《EXPERT OPINION ON INVESTIGATIONAL DRUGS》, vol. 22, no. 1, 4 November 2012 (2012-11-04), pages 149 - 159, XP009535062, DOI: 10.1517/13543784.2013.749236 *
沈沅，等: ""瑞喹莫德(R848)具有更强的免疫佐剂效应"", 《细胞与分子免疫学杂志》, no. 5, 18 May 2017 (2017-05-18), pages 19 - 24 *
许可见;等: ""Imiquimod和Resiquimod在皮肤科的应用"", 《中国医学科学院学报》, vol. 2006, no. 3, 30 June 2006 (2006-06-30), pages 147 - 149 *

Also Published As

Publication number Publication date
WO2022047083A1 (en) 2022-03-03
KR20230057409A (ko) 2023-04-28
AU2021332350A1 (en) 2023-03-16
EP4203962A4 (en) 2024-08-21
CA3192776A1 (en) 2022-03-03
US20230346775A1 (en) 2023-11-02
JP2023539625A (ja) 2023-09-15
EP4203962A1 (en) 2023-07-05
WO2022047083A9 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
JP6812512B2 (ja) 癌を治療するためのｐｄ−１アンタゴニストおよびｉｄｏ１阻害剤の組み合わせ
US20250000853A1 (en) Combination of a pd-1 antagonist and a vegf-r/fgfr/ret tyrosine kinase inhibitor for treating cancer
CN116056710A (zh) 用tlr激动剂治疗癌症
JP2020117524A (ja) 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用
JP7691418B2 (ja) 癌を治療するためのＰＤ－１アンタゴニスト、ＶＥＧＦＲ／ＦＧＦＲ／ＲＥＴチロシンキナーゼ阻害剤、及びＣＢＰ／β－カテニン阻害剤の組合せ
KR20230023810A (ko) 암을 치료하기 위한 pd-1 길항제 및 vegfr 억제제의 조합
JP2024028805A (ja) がん処置のための坑ｉｌ－８抗体及び坑ｐｄ－１抗体を用いる組合せ治療
JP2018508516A (ja) がんを治療するための、ｐｄ−１アンタゴニスト及びエリブリンの組合せ
CN108602892A (zh) 使用抗-pd-1抗体和另一种抗癌剂的组合治疗肺癌
US20220178930A1 (en) Anti-galectin-9 antibodies and uses thereof
US11440959B2 (en) CD226 agonist antibodies
WO2019178438A1 (en) Abbv-621 in combination with anti-cancer agents for the treatment of cancer
US20200254037A1 (en) Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti pd-l1 antibody and an oncolytic virus
JP2021501150A (ja) 肝臓がんを治療するための組成物及び方法
US20240218066A1 (en) Use of anti-pd-1 antibody in combination with first-line chemotherapy in treatment of advanced non-small cell lung cancer
US20260055200A1 (en) Combination therapies
US20250177352A1 (en) Combination treatment for cancer
RU2838452C1 (ru) Комбинация антагониста pd-1, ингибитора тирозинкиназы vegfr/fgfr/ret и ингибитора cbp/бета-катенина для лечения рака
KR20260019418A (ko) 암 치료 반응성의 지표 바이오마커로서의 혈장 tctp
HK40121853A (zh) 用抑制半乳糖凝集素-9的抗体治疗血液恶性肿瘤
HK40021784A (en) Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti pd-l1 antibody and an oncolytic virus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination